List of signals discussed at PRAC since September 2012
List of signals discussed at PRAC since September 2012
List of signals discussed at PRAC since September 2012
Human medicines European public assessment report (EPAR): Bridion, sugammadex, Neuromuscular Blockade, Date of authorisation: 25/07/2008, Revision: 22, Status: Authorised
Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Dementia;Alzheimer Disease;Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Lymphoma, Mantle-Cell;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 21/10/2014, Revision: 31, Status: Authorised
Good clinical practice (GCP) inspection procedures
Human medicines European public assessment report (EPAR): Lenalidomide Accord, lenalidomide, Multiple Myeloma, Date of authorisation: 20/09/2018, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 09/12/2021, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 22/11/2018, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Respiratory Tract Infections;Cystic Fibrosis, Date of authorisation: 18/02/2019, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): LysaKare, arginine,lysine, Radiation Injuries, Date of authorisation: 25/07/2019, Revision: 4, Status: Authorised